Search Results - "Toi, Yukihiro"

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort by Naqash, Abdul Rafeh, Ricciuti, Biagio, Owen, Dwight H., Florou, Vaia, Toi, Yukihiro, Cherry, Cynthia, Hafiz, Maida, De Giglio, Andrea, Muzaffar, Mavish, Patel, Sandip H., Sugawara, Shunichi, Burkart, Jarred, Park, Wungki, Chiari, Rita, Sugisaka, Jun, Otterson, Gregory A., de Lima Lopes, Gilberto, Walker, Paul R.

“…Background Immune-related adverse events (irAEs) comprise a distinct spectrum of auto-inflammatory manifestations triggered due to immune checkpoint inhibitors…”
Get full text

Nivolumab retreatment in non-small cell lung cancer patients who responded to prior immune-checkpoint inhibitors and had ICI-free intervals (WJOG9616L) by Akamatsu, Hiroaki, Teraoka, Shunsuke, Takamori, Shinkichi, Miura, Satoru, Hayashi, Hidetoshi, Hata, Akito, Toi, Yukihiro, Shiraishi, Yoshimasa, Mamesaya, Nobuaki, Sato, Yuki, Furuya, Naoki, Oyanagi, Jun, Koh, Yasuhiro, Misumi, Toshihiro, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko

“…To explore the efficacy of retreatment with immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) patients who responded to prior…”
Get full text

Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non–small cell lung cancer patients with impaired renal function: RESTART trial by Shiraishi, Yoshimasa, Kishimoto, Junji, Shimose, Takayuki, Toi, Yukihiro, Sugawara, Shunichi, Okamoto, Isamu

“…Abstract Background  First-line treatment of nonsquamous non–small cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy…”
Get full text

Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring by Katsume, Yumi, Isawa, Tsuyoshi, Toi, Yukihiro, Fukuda, Ryo, Kondo, Yasuteru, Sugawara, Shunichi, Ootomo, Tatsushi

“…Pembrolizumab, a humanized monoclonal IgG4 antibody directed against programmed death-1, is an immune checkpoint inhibitor that has been introduced for the…”
Get full text

Association between immune-related adverse event timing and treatment outcomes by Hsiehchen, David, Naqash, Abdul Rafeh, Espinoza, Magdalena, Von Itzstein, Mitchell S., Cortellini, Alessio, Ricciuti, Biagio, Owen, Dwight H., Laharwal, Mehak, Toi, Yukihiro, Burke, Michael, Xie, Yang, Gerber, David E.

“…The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) is highly variable. Although the development of irAE has…”
Get full text

Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase by Inui, Naoki, Toi, Yukihiro, Yoneshima, Yasuto, Morise, Masahiro, Hata, Akito, Kubota, Kaoru, Saeki, Toshiaki, Tamura, Tomohide

“…Introduction Fosnetupitant is a novel neurokinin 1 receptor antagonist (NK 1 RA) with favorable antiemetic efficacy in patients receiving emetogenic…”
Get full text

Anti-nuclear antibody and a granuloma could be biomarkers for iCIs-related hepatitis by anti-PD-1 treatment by Kondo, Yasuteru, Akahira, Junichi, Morosawa, Tatsuki, Toi, Yukihiro, Endo, Akashi, Satio, Hiroaki, Endo, Mareyuki, Sugawara, Shunichi, Tanaka, Yasuhito

“…It has been reported that various kinds of immune checkpoint inhibitors (iCIs) could induce immune-related liver damage. We should focus on the programmed cell…”
Get full text

Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers by Aiba, Tomoiki, Hattori, Chieko, Sugisaka, Jun, Shimizu, Hisashi, Ono, Hirotaka, Domeki, Yutaka, Saito, Ryohei, Kawana, Sachiko, Kawashima, Yosuke, Terayama, Keisuke, Toi, Yukihiro, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Suzuki, Yutaka, Niida, Atsushi, Sugawara, Shunichi

“…Although anti-PD-1/PD-L1 monotherapy has achieved clinical success in non-small cell lung cancer (NSCLC), definitive predictive biomarkers remain to be…”
Get full text

Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204 by Toi, Yukihiro, Kobayashi, Takao, Harada, Toshiyuki, Nakagawa, Taku, Mori, Yoshiaki, Kuda, Tomoya, Sugawara, Shunichi

“…Background Diarrhea post-antibiotic use is primarily attributed to mucosal lesions induced by Clostridium ( Clostridioides) difficile ( C. difficile )…”
Get full text

Observational study of chemotherapy-induced Clostridium difficile infection in patients with lung cancer by Toi, Yukihiro, Sugawara, Shunichi, Kobayashi, Takao, Terayama, Keisuke, Honda, Yoshihiro

“…Background Diarrhea post-antibiotic use is primarily attributed to Clostridium difficile infection (CDI)-induced mucosal lesions, and evidence of CDI in…”
Get full text

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge by Sugisaka, Jun, Toi, Yukihiro, Kawashima, Yosuke, Domeki, Yutaka, Aiba, Tomoiki, Kawana, Sachiko, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Sugawara, Shunichi

“…Abstract Background There is no well‐established late‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC). Therefore, we retrospectively…”
Get full text

Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases by Murakami, Yosuke, Kawashima, Yosuke, Chiba, Shinji, Hara, Shuichiro, Yamazaki, Yusuke, Doman, Tsuyoshi, Saito, Shin, Odaka, Tetsuo, Ogasawara, Takahiro, Shimizu, Hisashi, Sugisaka, Jun, Aiba, Tomoiki, Toi, Yukihiro, Yamanda, Shinsuke, Kimura, Yuichiro, Sugawara, Shunichi

“…Background Anaplastic lymphoma kinase (ALK)‐positive lung cancer has a better long‐term prognosis with ALK‐inhibitor than other lung cancers. However,…”
Get full text

Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort by Naqash, Abdul Rafeh, Ricciuti, Biagio, Owen, Dwight H., Florou, Vaia, Toi, Yukihiro, Cherry, Cynthia, Hafiz, Maida, De Giglio, Andrea, Muzaffar, Mavish, Patel, Sandip H., Sugawara, Shunichi, Burkart, Jarred, Park, Wungki, Chiari, Rita, Sugisaka, Jun, Otterson, Gregory A., de Lima Lopes, Gilberto, Walker, Paul R.

“…The original version of this article unfortunately contained a mistake. The second sentence of the section “irAEs and ICI efficacy” should read as…”
Get full text

Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome by Minami, Soichiro, Kawashima, Yosuke, Munakata, Yasuhiko, Matsuno, Masahiro, Hara, Shuichiro, Yamazaki, Yusuke, Doman, Tsuyoshi, Saito, Shin, Odaka, Tetsuo, Ogasawara, Takahiro, Shimizu, Hisashi, Sugisaka, Jun, Aiba, Tomoiki, Toi, Yukihiro, Yamanda, Shinsuke, Kimura, Yuichiro, Sugawara, Shunichi

“…ABSTRACT Background The expansion of preoperative immunochemotherapy has led to an increase in the number of patients with lung cancer receiving immune…”
Get full text

Serial 6-month change in forced vital capacity predicts subsequent decline and mortality in Japanese patients with newly diagnosed idiopathic pulmonary fibrosis by Toi, Yukihiro, Takei, Reoto, Kimura, Tomoki, Kataoka, Kensuke, Matsuda, Toshiaki, Yokoyama, Toshiki, Fukuoka, Junya, Johkoh, Takeshi, Kondoh, Yasuhiro

“…The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by a progressive decline in lung function; however, predicting changes in lung…”
Get full text

Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer by Ono, Kana, Ono, Hirotaka, Toi, Yukihiro, Sugisaka, Jun, Aso, Mari, Saito, Ryohei, Kawana, Sachiko, Aiba, Tomoiki, Odaka, Tetsuo, Matsuda, Suguru, Saito, Shin, Narumi, Akane, Ogasawara, Takahiro, Shimizu, Hisashi, Domeki, Yutaka, Terayama, Keisuke, Kawashima, Yosuke, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Honda, Yoshihiro, Sugawara, Shunichi

“…Background The association between the development of checkpoint inhibitor pneumonitis (CIP) with tumor response and survival has remained unclear so far. The…”
Get full text

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060 by Tozuka, Takehiro, Minegishi, Yuji, Yamaguchi, Ou, Watanabe, Kana, Toi, Yukihiro, Saito, Ryota, Nagai, Yoshiaki, Tamura, Yosuke, Shoji, Tetsuaki, Odagiri, Haruka, Ebi, Noriyuki, Sakai, Kosuke, Kanaji, Nobuhiro, Izumi, Makoto, Soda, Sayo, Watanabe, Satoshi, Morita, Satoshi, Kobayashi, Kunihiko, Seike, Masahiro

“…Immune checkpoint inhibitor (ICI)–based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival benefit of…”
Get full text

Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors by Isawa, Tsuyoshi, Toi, Yukihiro, Sugawara, Shunichi, Taguri, Masataka, Toyoda, Shigeru

“…Cardiovascular immune-related adverse events (CV-irAEs) associated with immune checkpoint inhibitors (ICIs) may have been underreported given that most…”
Get full text

Association of Immune‐Related Adverse Events with Clinical Benefit in Patients with Advanced Non‐Small‐Cell Lung Cancer Treated with Nivolumab by Toi, Yukihiro, Sugawara, Shunichi, Kawashima, Yosuke, Aiba, Tomoiki, Kawana, Sachiko, Saito, Ryohei, Tsurumi, Kyoji, Suzuki, Kana, Shimizu, Hisashi, Sugisaka, Jun, Ono, Hirotaka, Domeki, Yutaka, Terayama, Keisuke, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Honda, Yoshihiro

“…Background Immune‐related adverse events (irAEs) are frequently observed with nivolumab monotherapy. This study aimed to evaluate whether the development of…”
Get full text

Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer by Toi, Yukihiro, Sugawara, Shunichi, Sugisaka, Jun, Ono, Hirotaka, Kawashima, Yosuke, Aiba, Tomoiki, Kawana, Sachiko, Saito, Ryohei, Aso, Mari, Tsurumi, Kyoji, Suzuki, Kana, Shimizu, Hisashi, Domeki, Yutaka, Terayama, Keisuke, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Honda, Yoshihiro

“…Administration of anti-programmed cell death protein 1 (anti-PD-1) is now standard therapy in advanced non-small cell lung cancer (NSCLC). However, immune…”
Get more information